CoChat

Underutilisation of ACE inhibitors in patients with congestive heart failure.

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

Abstract

Congestive heart failure (CHF) is associated with substantial morbidity and mortality, and is the only major cardiovascular disease increasing in prevalence. Despite abundant evidence to support their efficacy and cost-effectiveness, angiotensin-converting enzyme (ACE) inhibitors are sub-optimally used in patients with CHF. This paper reviews the evidence for the sub-optimal use of ACE inhibitors in patients with CHF, the factors contributing to this, and its implications for health systems. A systematic review of all articles assessing practice patterns (specifically the use of ACE inhibitors in CHF) identified by MEDLINE, search of bibliographies, and contact with content experts was undertaken. 37 studies have documented the use of ACE inhibitors in patients with CHF. Studies assessing use among all patients with CHF document 33% to 67% (median 51%) of all patients discharged from hospital and 10% to 36% (median 26%) of community dwelling patients were prescribed ACE inhibitors. Rates of ACE inhibitor use range from 43% to 90% (median of 71%) amongst those discharged from hospital having known systolic dysfunction, and from 67% to 95% (median of 86%) for those monitored in specialty clinics. Moreover, the dosages used in the 'real world' are substantially lower than those proven efficacious in randomised, controlled trials, with evaluations reporting only a minority of patients achieving target doses and/or an overall mean dose achieved to be less than one-half of the target dose. Factors predicting the use and optimal dose administration of ACE inhibitors are identified, and include variables relating to the setting (previous hospitalisation, specialty clinic follow-up), the physician (cardiology specialty versus family practitioner or general internist, board certification), the patient (increased severity of symptoms, male, younger), and the drug (lower frequency of administration). In light of the substantial evidence for reductions in morbidity and mortality, clearly, the prescription of ACE inhibitors is sub-optimal. Wide variability in ACE inhibitor use is noted, with higher rates consistently reported among patients having systolic dysfunction confirmed by an objective assessment--an apparent minority of the those having CHF. Optimisation of the prescription of proven efficacious therapies has the potential to confer a substantial reduction in the total cost of care for patients with CHF by reducing hospitalisations and lengths of hospital stays. It is likely that only multifaceted programs targeted toward the population at large will yield benefits to the healthcare system, given the widespread nature of the sub-optimal prescription of therapies proven effective in the management of patients with CHF.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003495-200161140-00002

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 86 references

Research works printed but not linked: 15

  1. Ackman, 1995, Prairie Med J, 65, 109
  2. Brophy, 1992, Can J Cardiol, 8, 495
  3. Johnstone, 1994, Can J Cardiol, 10, 613
  4. 1987, N Engl J Med, 316, 429
  5. Paul, 1994, Arch Intern Med, 154, 1143, 10.1001/archinte.1994.00420100129016 · doi:10.1001/archinte.1994.00420100129016 · Paper page
  6. 1999, Am J Cardiol, 83, 2A
  7. Croft, 1997, J Fam Pract, 44, 382
  8. Ghali, 1997, J La State Med Soc, 149, 474
  9. Houghton, 1997, J Royal Col Phys London, 31, 276
  10. Krumholz, 1997, Arch Intern Med, 157, 2242, 10.1001/archinte.1997.00440400092011 · doi:10.1001/archinte.1997.00440400092011 · Paper page
  11. Mair, 1996, Br J Gen Pract, 46, 77
  12. Parameshwar, 1992, J Royal Coll Phys London, 26, 139
  13. Parameshwar, 1992, Br J Gen Pract, 42, 287
  14. OReilly, 1999, CMAJ, 160, 1039
  15. McMurray, 1993, Br J Med Econ, 6, 91

Cited by

See all 73

Metadata

Authors
Bungard, T. J., McAlister, F. A., Johnson, J. A., & Tsuyuki, R. T.
Affiliations
University of Alberta (CA)
Corresponding author
Tsuyuki, Ross T.
Venue
Drugs
Published
2001
Volume
61
Issue
14
Pages
2021-2033
ISSN
0012-6667 (ISSN-L)
OpenAlex
W1980049759
Cited by
73
References
86
Citations by year
2024: 1 · 2023: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 2
FWCI
1.13
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords
congestive heart failure, ACE inhibitors, prescribing patterns, dose optimization, systolic dysfunction, health care costs, hospitalization, physician specialty, patient factors, medication adherence, quality of care, guideline adherence, community-dwelling patients, cost-effectiveness, multicomponent intervention, patient education
MeSH terms
Angiotensin-Converting Enzyme Inhibitors, Dose-Response Relationship, Drug, Drug Administration Schedule, Heart Failure, Humans, Morbidity, Practice Patterns, Physicians', Patient Selection, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Underutilisation of ACE inhibitors in patients with congestive heart failure. https://app.cochat.ai/papers/10.2165/00003495-200161140-00002
The paper
Bungard, T. J., McAlister, F. A., Johnson, J. A., & Tsuyuki, R. T. (2001). Underutilisation of ACE inhibitors in patients with congestive heart failure. Drugs. https://doi.org/10.2165/00003495-200161140-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.